BUZZ-Insmed jumps after forecasting preliminary 2025 revenue above estimates

Reuters01-09

BUZZ-<a href="https://laohu8.com/S/INSM">Insmed</a> jumps after forecasting preliminary 2025 revenue above estimates

** Shares of drugmaker Insmed INSM.O rise 11.6% to $190 premarket

** INSM expects 2025 revenue to be $606.4 million, compared to analysts' estimates of $513.5 million - data compiled by LSEG

** Leerink Partners says Insmed blew consensus estimates out of the water "for the first full quarter of Brinsupri's launch, with sales of $144.6 million"

** Brinsupri was approved by U.S. FDA in August 2025 to treat type of lung disease called non-cystic fibrosis bronchiectasis

** Expects 2025 revenue for its lead drug, Arikayce, to be 433.8 million vs estimates of $428.3 million

** Expects 2026 revenue for Arikayce to be between $450 million and $470 million, compared to estimates of $499.1 million

** "The actual results could be materially different from these preliminary unaudited financial results" - INSM

** "This launch is still in the early innings, and we remain positive on this story for not only Brinsupri but the suite of catalysts expected over the next 12+ months," Leerink adds

** As of last close, stock has more than doubled in past 12 months

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602237430?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 22:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602237430","market":"nz","top_or_hot":-1,"title":"BUZZ-Insmed jumps after forecasting preliminary 2025 revenue above estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/INSM\">Insmed</a> jumps after forecasting preliminary 2025 revenue above estimates</title></head><body><p>** Shares of drugmaker Insmed <span>INSM.O</span> rise 11.6% to $190 premarket</p><p>** INSM expects 2025 revenue to be $606.4 million, compared to analysts' estimates of $513.5 million - data compiled by LSEG </p><p>** Leerink Partners says Insmed blew consensus estimates out of the water \"for the first full quarter of Brinsupri's launch, with sales of $144.6 million\"</p><p>** Brinsupri was <span>approved by U.S. FDA</span> in August 2025 to treat type of lung disease called non-cystic fibrosis bronchiectasis</p><p>** Expects 2025 revenue for its lead drug, Arikayce, to be 433.8 million vs estimates of $428.3 million </p><p>** Expects 2026 revenue for Arikayce to be between $450 million and $470 million, compared to estimates of $499.1 million </p><p>** \"The actual results could be materially different from these preliminary unaudited financial results\" - INSM</p><p>** \"This launch is still in the early innings, and we remain positive on this story for not only Brinsupri but the suite of catalysts expected over the next 12+ months,\" Leerink adds</p><p>** As of last close, stock has more than doubled in past 12 months</p><p> (Reporting by Siddhi Mahatole)</p><p> ((siddhi.mahatole@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Insmed jumps after forecasting preliminary 2025 revenue above estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Insmed jumps after forecasting preliminary 2025 revenue above estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-09 22:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/INSM\">Insmed</a> jumps after forecasting preliminary 2025 revenue above estimates</title></head><body><p>** Shares of drugmaker Insmed <span>INSM.O</span> rise 11.6% to $190 premarket</p><p>** INSM expects 2025 revenue to be $606.4 million, compared to analysts' estimates of $513.5 million - data compiled by LSEG </p><p>** Leerink Partners says Insmed blew consensus estimates out of the water \"for the first full quarter of Brinsupri's launch, with sales of $144.6 million\"</p><p>** Brinsupri was <span>approved by U.S. FDA</span> in August 2025 to treat type of lung disease called non-cystic fibrosis bronchiectasis</p><p>** Expects 2025 revenue for its lead drug, Arikayce, to be 433.8 million vs estimates of $428.3 million </p><p>** Expects 2026 revenue for Arikayce to be between $450 million and $470 million, compared to estimates of $499.1 million </p><p>** \"The actual results could be materially different from these preliminary unaudited financial results\" - INSM</p><p>** \"This launch is still in the early innings, and we remain positive on this story for not only Brinsupri but the suite of catalysts expected over the next 12+ months,\" Leerink adds</p><p>** As of last close, stock has more than doubled in past 12 months</p><p> (Reporting by Siddhi Mahatole)</p><p> ((siddhi.mahatole@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nL4N3YA0ZQ:1","article_id":"2602237430","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602237430","pubTimestamp":1767968840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Insmed jumps after forecasting preliminary 2025 revenue above estimates** Shares of drugmaker Insmed INSM.O rise 11.6% to $190 premarket** INSM expects 2025 revenue to be $606.4 million, compared to analysts' estimates of $513.5 million - data compiled by LSEG ** Leerink Partners says Insmed blew consensus estimates out of the water \"for the first full quarter of Brinsupri's launch, with sales of $144.6 million\"** Brinsupri was approved by U.S. FDA in August 2025 to treat type of lung disease called non-cystic fibrosis bronchiectasis** Expects 2025 revenue for its lead drug, Arikayce, to be 433.8 million vs estimates of $428.3 million ** Expects 2026 revenue for Arikayce to be between $450 million and $470 million, compared to estimates of $499.1 million ** \"The actual results could be materially different from these preliminary unaudited financial results\" - INSM** \"This launch is still in the early innings, and we remain positive on this story for not only Brinsupri but the suit","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","INSM":"Insmed","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"BUZZ-Insmed预测2025年初步收入高于预期后股价上涨","themeId":"87f58df0cea45f9dc7f6df99dc1f4be0","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":0.9},"content_text":"BUZZ-Insmed jumps after forecasting preliminary 2025 revenue above estimates** Shares of drugmaker Insmed INSM.O rise 11.6% to $190 premarket** INSM expects 2025 revenue to be $606.4 million, compared to analysts' estimates of $513.5 million - data compiled by LSEG ** Leerink Partners says Insmed blew consensus estimates out of the water \"for the first full quarter of Brinsupri's launch, with sales of $144.6 million\"** Brinsupri was approved by U.S. FDA in August 2025 to treat type of lung disease called non-cystic fibrosis bronchiectasis** Expects 2025 revenue for its lead drug, Arikayce, to be 433.8 million vs estimates of $428.3 million ** Expects 2026 revenue for Arikayce to be between $450 million and $470 million, compared to estimates of $499.1 million ** \"The actual results could be materially different from these preliminary unaudited financial results\" - INSM** \"This launch is still in the early innings, and we remain positive on this story for not only Brinsupri but the suite of catalysts expected over the next 12+ months,\" Leerink adds** As of last close, stock has more than doubled in past 12 months (Reporting by Siddhi Mahatole) ((siddhi.mahatole@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602237430","isCrawlerRequest":true}